Marseille

• Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting
  2023-508644-22-00 7 2023-02-28 Advance Solid Tumors
• Evaluation of the Efficacy of an Intra-articular Injection of Autologous Microfat Combined With Autologous Platelet-enriched Plasma in the T … Recruiting
  2024-516239-28-00 4 2023-02-17 Radiocarpal Osteoarthritis
• Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting
  2023-507233-19-00 10 2023-02-16 Treatment of IgAN
• Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting
  2023-509332-26-00 4 2023-02-16 Lupus Nephritis Class III-IV, +/- V
• Chemotherapy for the treatment of standard risk adult medulloblastomas Recruiting
  2024-513243-85-00 4 2023-02-03 Adult medulloblastoma
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut … Recruiting
  2023-505634-94-00 10 2023-02-02 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o … Recruiting
  2024-514328-18-00 7 2022-12-06 Spinocerebellar ataxia types 1, 3 and Huntington's disease
• Early discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosis Recruiting
  2024-514353-30-00 6 2022-11-25 Idiopathic retroperitoneal fibrosis
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting
  2024-511884-27-00 3 2022-11-09 CD205+ve recurrent and/or metastatic tumor types including but not lim
• Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting
  2023-508425-28-00 4 2022-10-24 Chronic Inflammatory Demyelinating Polyneuropathy
• INNOVATIVE TREATMENT OF SCARRED VOCAL FOLDS BY LOCAL INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION: EFFICACY VERSUS PLAC … Recruiting
  2024-517384-24-00 4 2022-09-22 SCARRED VOCAL FOLDS
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• MetroWilms Recruiting
  2022-502687-20-00 4 2022-09-14 Wilms tumor
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting
  2024-511899-32-00 10 2022-08-31 Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
• Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD Recruiting
  2023-508534-33-00 10 2022-06-16 Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Recruiting
  2024-511201-32-00 5 2022-06-13 Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
• RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting
  2023-503267-42-00 5 2022-06-10 Patients with a histological diagnosis of mismatch- repair deficient h
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting
  2024-513986-38-00 4 2022-06-01 Locally advanced or metastatic papillary cell carcinoma (PRCC)

Showing 697–720 of 1,485 trials